To marketing authorisation holders and their representatives in Iceland: The European Medicines Agency improves and updates the database for adverse reactions, EudraVigilance - 14.6.2017

The European Medicines Agency (EMA) will improve and update EudraVigilance, the database for collection and administration of adverse reaction reports for pharmaceutical companies and authorities. It is important that marketing authorisation holders and representatives become familiar with technical functionalities in time. New EudraVigilance will be launched on 22 November 2017. 

Additional Risk Minimisation Measures (aRMM) - 2.6.2017

From 1 June 2017 IMA will take seven days to ensure that all relevant documents are enclosed in an application for aRMM evaluation. This is done to facilitate IMAs review of the material.

Malta and Iceland strengthen cooperation on medicines regulation - 26.5.2017

The Malta Medicines Authority made a cooperation agreement with the Icelandic Medicines Agency in an effort to strengthen capacity for medicines authorisations through joint assessment.  The agreement will facilitate mutual training for experts and explore the feasibility of conducting joint inspections.

See all